BI buys rights to NASH-targeted tech from Singapore's Enleof...

Boehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known as NASH, a prime target for many pharma compani

Boehringer cleared to manufacture BeiGene's cancer drug for ...

Boehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed to strengthen the country’s domestic pharma infrastructure.

Boehringer, Lilly start acute heart failure trial with Jardi...

Lilly and Boehringer rejig diabetes alliance as Jardiance so...

Eli Lilly and Boehringer Ingelheim have changed the terms of their diabetes alliance to focus their energies on developing their big-selling Jardiance pill.

Boehringer Ingelheim to present data at RAS Summit Europe

RAS- Targeted Drug Discovery Europe Conference

Which big pharma firms are best at digital?

New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital channels – with Bayer, Pfizer and Boehringer Ingelheim coming out